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Abstract: IgE antibodies are a pivotal factor in pathophysiology of allergic diseases, and the 
possibility of reducing their level by anti-IgE has long been envisioned. Following several 
attempts, an effective biologic agent was obtained with the recombinant humanized mono-
clonal antibody (rhuMAb)-E25, known as omalizumab. A number of controlled clinical trials 
demonstrated its efﬁ  cacy and safety in the treatment of severe allergic asthma uncontrolled by 
standard drug treatment with maximal recommended doses, and treatment with omalizumab is 
currently included in international guidelines on asthma management. Other studies reported a 
clear effectiveness also in allergic rhinitis, but the cost of the anti-IgE treatment suggests its use 
in patients with rhinitis concomitant with asthma. Other indications to be further investigated 
are skin disorders such as atopic dermatitis and IgE-mediated urticaria, as well as adverse 
reactions to foods, with a particularly important role in preventing food-induced anaphylaxis. 
Finally, there are data indicating the usefulness of omalizumab when used in combination with 
allergen speciﬁ  c immunotherapy, in terms of reducing the adverse reactions to treatment and 
increasing the clinical efﬁ  cacy.
Keywords: IgE, anti-IgE, omalizumab, allergic asthma, allergic rhinitis, atopic dermatitis, food 
allergy, allergen immunotherapy
Introduction
Immunoglobulin E (IgE) was the last of the immunoglobulin isotypes to be discovered, 
thanks to the studies of Teruko and Kimishige Ishizaka in US (Ishizaka et al 1966) 
and of Johansson and Bennich in Europe (Johansson et al 1967). This isotype was thus 
ﬁ  nally recognized as the antibody responsible for allergic reactions – called “reagine” 
after the experiments on passive transport in the 1920s (Prausnitz et al 1921) – and 
designated γE-globulin after the antigen E from ragweed, to which the antibody from 
allergic patients was directed (Ishizaka et al 1966).
IgE antibody has a pivotal role in type I hypersensitivity reactions, inducing through 
the binding with its high afﬁ  nity receptor (FCεRI) the release of inﬂ  ammatory media-
tors such as histamine, leukotrienes, prostaglandins, and others, from mast cells and 
basophils (Siraganian 1993), which in turn induce their typical target organ effects, 
the most important being vasodilation and bronchoconstriction. IgE appear necessary 
but not sufﬁ  cient to cause allergic symptoms, as suggested by the common observation 
that there are subjects in whom allergen-speciﬁ  c IgE are present but who demonstrate 
no clinical allergic symptoms. However, it has been possible to demonstrate in an 
epidemiological study that asthma is associated with serum IgE levels (Burrows et al 
1989), and that the quantity of circulating IgE is a critical factor, since symptomatic 
subjects have speciﬁ  c IgE levels higher than aymptomatic subjects, with variable 
cutoffs according to different allergens (Pastorello et al 1995).
The concept of treating the IgE-mediated allergies with anti-IgE antibodies was 
soon apparent and a method for generating monoclonal antibodies was introduced in the Biologics: Targets & Therapy 2008:2(1) 68
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seventies (Kohler et al 1975), but a number of problems had 
to be solved to achieve a feasible agent to be used in allergic 
subjects. The main problems were: i) the humanization, 
that is, to greatly reduce the murine component and thus the 
immunogenicity and the potential toxicity of the antibody; 
ii) the anaphylactogenic capacity, which is a characteristic of 
anti-IgE antibodies used in vitro to investigate the mediator 
release by mast cells and basophils; iii) the possible risk of 
parasitic infections, to which IgE exert a protective role.
After several attempts, the anti-IgE named recombinant 
humanized monoclonal antibody (rhuMAb)-E25, now known 
as omalizumab, proved to fulﬁ  l such requirements (Presta 
et al 1993). In fact, omalizumab (MW 150 kDa) contains 95% 
of a human IgG1 antibody. The speciﬁ  c antibody-binding 
site, making up  5% of the total molecule, is of murine 
origin (variable amino-terminal domains on both heavy and 
light chains) and represents the portion of omalizumab that 
binds to IgE. The binding site is the Cε3 domain of IgE, made 
up of six key amino acids that form a system of three loops; 
Cε3 is accessible only to free IgEs but not on the IgE bound 
to mast cells or basophils, where there is no access, as it is 
occupied by the FCεRI receptor (Schulman 2001). These two 
characteristics confer to this molecule low immunogenicity 
(due to an extremely low content of murine components) and 
non-complement binding properties (due to the human part 
of the molecule); moreover, it does not bind cell-surface IgE, 
thus avoiding the FCεRI cross-linking that could potentially 
lead to anaphylaxis. However, the issue of anaphylactic 
reactions will be discussed in detail later.
Concerning parasitic infections, in animal studies there 
are conﬂ  icting results: in an experiment IgE deﬁ  cient mice 
were signiﬁ  cantly more susceptible to infection from Schis-
tosoma mansoni (King et al 1997), while in another study 
the decrease of IgE obtained by anti-IgE abated the burden 
of infection by the same parasite (Amiri et al 1994). It is of 
interest that a recent study on omalizumab-treated allergic 
subjects at high risk of geohelminth infection found a slight 
increase in the incidence of infections (Cruz et al 2007). This 
suggests that patients with such risk should undergo accurate 
surveillance of parasitic infections, though infection severity 
and response to anti-helminthics appeared to be unaffected 
by omalizumab therapy.
Considering clinical use, the dosage of omalizumab is 
established in a range from 150 mg every 4 weeks to 375 mg 
every 2 weeks; individual dosing depends on the body weight 
and the target level of total IgE, up to 700 IU/mL. With such 
doses, a signiﬁ  cant reduction of free IgE occurs as early as 
24–48 hours from the ﬁ  rst administration by subcutaneous 
route (Jardieu et al 1999; Lin et al 2004), while a signiﬁ  cant 
inhibition of clinical symptoms – by a speciﬁ  c allergen 
challenge – occurs after 1 week (Lin et al 2004). At pres-
ent, according to the label indications, some patients might 
remain excluded from the administration of the drug because 
of levels of IgE   700 IU/mL, or because of high weight. In 
fact the recommended monthly dose is equal to 0.016 mg × 
body weight (kg) × IgE levels (IU/mL), and which may result 
in greater than 750 mg (maximum monthly dose).
As to safety issues, the possible damage from immune 
complexes has already been ruled out in phase I studies, 
which demonstrated that the IgE – anti-IgE complexes were 
small, did not precipitate, did not activate the complement 
because of their binding to the Cε3 and were eliminated 
with urine (Fox et al 1996). Frequency of adverse events, 
evaluated in more that 5000 patients, was comparable for any 
kind of event in omalizumab- and placebo-treated subjects 
(Deniz et al 2005). Some doubt was raised about a report 
of malignant neoplasms, but the rate of such pathology was 
below 1% in both omalizumab-treated and control patients, 
and a panel of oncologists stated the lack of relationship 
between neoplasms and study treatment.
During the clinical studies of phase II/III on allergic 
asthmatics, approximately 6700 patients received omali-
zumab. The most commonly reported reactions have been 
pain, swelling, itching, and erythema in the injection site, 
all of these short-lived and self-limited. Anaphylaxis has 
been reported as a possible adverse event, with a frequency 
of about 0.1%. In one of these reactions it was possible to 
achieve tolerance to omalizumab by desensitization, which 
was, however, followed by a serum sickness-like disease 
(Dreyfus et al 2006).
More cases have been reported after the launch of the drug 
in the US market (124 cases of anaphylaxis occurred over 
57300 patients treated from June 2003 to December 2006), 
and consequently the FDA added an additional warning 
about this risk. The frequency of anaphylaxis attributed to 
omalizumab use was estimated to be at least 0.2% of treated 
patients in the wild population. The discrepancy of this datum 
between clinical trial setting and the wild population could be 
due to the fact that some clinical trials considered a previous 
history of anaphylaxis as an exclusion criterion, leading to 
patients at higher risk not being enrolled in the trials.
Omalizumab should be administered in hospital setting, 
where this kind of emergency can be dealt with. Patients must 
be informed about the risk of anaphylaxis, an adverse reaction 
that is more frequent and life-threatening with other conven-
tional therapies: for instance, speciﬁ  c immunotherapy has Biologics: Targets & Therapy 2008:2(1) 69
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been reported to cause anaphylactic shock with a frequency of 
0.6%, and it can even – in 1 out of 2.5 million injections – be 
fatal (Mellerup et al 2000; Stokes et al 2006).
Moreover, considerating that the frequency and the 
severity of allergic reactions is higher in the asthma popula-
tion than in general population (Uguz et al 2005), we do not 
know which concomitant treatments were prescribed when 
the reactions happened and, above of all, we do not know 
the anaphylaxis past-history of these patients. The risk of 
anaphylaxis must be also compared with the real beneﬁ  ts 
that patients can obtain from this therapy, which has proved 
to halve the frequency of severe exacerbations that can pos-
sibly threaten the patients’ survival.
For clinical application, the ﬁ  rst objective of treatment 
indication for omalizumab was severe allergic asthma, but 
subsequent research has expanded this to include other IgE-
mediated diseases eligible for anti-IgE treatment, such as 
allergic rhinitis, skin disorders such as atopic dermatitis and 
urticaria, and adverse reactions to foods. Another emerging 
indication appears to be the use of omalizumab to improve 
the safety and efﬁ  cacy of allergen immunotherapy.
Review objectives
The articles to be considered in the review were researched 
by using the terms “anti-IgE, omalizumab, allergic asthma, 
allergic rhinitis, atopic dermatitis, food allergy, anaphylaxis, 
allergen immunotherapy” in the databases PubMed and 
Embase.
Omalizumab in allergic asthma
The current indications for the treatment of asthma, 
according to GINA international guidelines, aim to achieve 
and maintain clinical control of the disease, using controller 
and reliever drugs (Global Initiative for Asthma 2007). 
Controllers drugs are the mainstay for the chronic treatment, 
as their action has contrasting effects on the chronic 
inﬂ  ammation of the bronchi. These drugs include: inhaled 
and systemic glucocorticosteroids, leukotriene modiﬁ  ers, 
long-acting inhaled beta2-agonists in combination with inhaled 
glucocorticosteroids, sustained-release theophylline, and 
cromones. Inhaled glucocorticosteroids are the most effective 
controller medications currently available, but a minority of 
patients fail to achieve control despite the chronic use of these 
drugs. This group of patients, suffering from allergic asthma 
(with a sensitization to at least one perennial aeroallergen) 
not controlled by drug therapy with maximal recommended 
dosage of inhaled corticosteroids plus bronchodilators, has 
the indication to be treated with omalizumab. A number of 
studies have demonstrated the beneﬁ  cial effects of reducing 
the serum levels of IgE, ﬁ  rst by the model of allergen challenge 
(Boulet et al 1997; Fahy et al 1997) and then by clinical trials 
in adults and children (Milgrom et al 1999; Solèr et al 2001; 
Busse et al 2001; Buhl et al 2002; Finn et al 2003; Corren et al 
2003; Bousquet et al 2005; Holgate et al 2005; Humbert et al 
2005) with severe asthma. The results obtained in actively 
treated compared to placebo-treated patients in these trials 
can be summarized as follows: a signiﬁ  cant reduction of doses 
of inhaled corticosteroids (ICS), with a greater percentage of 
actively treated patients able to withdraw from ICS completely; 
a signiﬁ  cant reduction in asthma-related emergency room visits 
and hospitalizations; and a signiﬁ  cant improvement in asthma-
related quality of life (Holgate et al 2005). The INNOVATE 
study has also succeeded in demonstrating that patients with 
more severe forms of allergic asthma, treated with high dose 
ICS and long-acting β2-adrenergic agonists, could best take 
advantage from omalizumab as an add-on therapy. In fact 
it has been proven that asthma exacerbation rates decrease 
signiﬁ  cantly, as well as the need for rescue medications, and 
QoL improves (Humbert et al 2005).
Today, the need for scientiﬁ  c evidence for any treatment 
is fully met by the tool of meta-analysis. The most recent 
Cochrane meta-analysis included all 14 randomized controlled 
trials up to February 2006 (Walker et al 2006), with an overall 
number of 3143 patients with allergic asthma, mostly caused by 
perennial allergens, high levels of IgE, and at least one positive 
allergy skin test to aeroallergens. Treatment with omalizumab 
was associated with a significant decrease in free IgE 
compared with placebo and with signiﬁ  cant changes in clinical 
parameters, assessed by odds ratio (OR). In particular, there 
were signiﬁ  cant differences in favor of omalizumab concerning 
the number of patients able to reduce ICS by over 50% (OR 
2.50, 95% CI 2.02–3.10), the number of patients completely 
withdrawing daily ICS intake (OR 2.50, 95% CI 2.00–3.13), 
and the likelihood of suffering an asthma exacerbation (OR 
0.52, 95% CI 0.41–0.65). The reviewers pointed out that the 
signiﬁ  cant effectiveness of omalizumab must be considered 
in the light of its high cost, and this economic issue has also 
been considered by Brown et al who demonstrated that add-on 
omalizumab therapy is cost-effective in patients with severe 
persistent allergic asthma (Brown et al 2007).
Another important observation in asthma is the ability of 
omalizumab to act on airway hyper-responsiveness in vitro. 
A recent study investigated this in human bronchi incubated 
in normal or asthmatic serum containing different concentra-
tions of omalizumab, and showed that both speciﬁ  c (ie, to 
Dermatophagoides pteronyssinus) and non-speciﬁ  c bronchial Biologics: Targets & Therapy 2008:2(1) 70
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hyper-responsiveness following passive sensitization were 
signiﬁ  cantly inhibited by omalizumab (Berger et al 2007). 
These properties still have to be demonstrated in vivo, as, 
though its anti-inﬂ  ammatory effect, omalizumab did not 
prove to reduce airways hyper-responsivenss in asthmatic 
patients (Djukanovic et al 2004).
In the in vitro study by Berger et al omalizumab decreased 
the number of IgE-bearing cells and mast cell degranulation 
(Berger et al 2007). The immunologic effects of anti-IgE 
treatment were also investigated in other studies. Fahy et al 
found a signiﬁ  cant decrease from baseline in eosinophils – 
which are the leukocytes mainly recruited in IgE-mediated 
inﬂ  ammation – measured in blood and in induced sputum (Fahy 
et al 1997) and the effect of omalizumab on eosinophils was 
conﬁ  rmed, with signiﬁ  cant difference compared with placebo, 
along with a signiﬁ  cant decrease of IL-13, a cytokine involved 
in eosinophil activation, and decreases in IL-5 and IL-8 (Noga 
et al 2006). Another study reported a highly signiﬁ  cant differ-
ence compared with placebo concerning the reduction in mean 
percentage of eosinophils in induced sputum achieved by omali-
zumab, paralleled by a decrease in free IgE to under 50 ng/mL 
and by a strong reduction in IgE+ cells in the submucosa from 
bronchial biopsies (Djukanovic et al 2004). Moreover, a signiﬁ  -
cant decrease in cell surface IL-4 associated with the reduction 
in submucosal eosinophil number was detected (Djukanovic 
et al 2004). From these data it is reasonable to assume that a 
major decrease in free IgE induces, through FCεRI+ cells, a 
change in inﬂ  ammatory response to the speciﬁ  c allergen(s) 
and in particular in the eosinophil recruitment and activation 
mediated by IL-4, IL-5, IL-8, and IL-13.
A point of the utmost interest is the possible prediction 
of which patients will respond to omalizumab: an analysis 
on 1070 patients suggested that baseline characteristics do 
not reliably predict beneﬁ  t from the treatment with omali-
zumab. Currently the most meaningful measure of response 
to therapy is a physician's overall assessment after 16 weeks 
of treatment (Bousquet et al 2004). Another study evaluated 
the response to omalizumab in patients not well controlled 
by treatments including long-acting beta2-agonists, antileu-
kotrienes, and oral corticosteroids, and found better asthma 
control in subjects who received the anti-IgE compared with 
drug therapy only (Ayres et al 2004).
Other current and future 
applications of omalizumab
Allergic rhinitis
Considering the strict relationship between allergic rhinitis 
and asthma, which often coexist, it is reasonable to expect 
anti-IgE treatment to be effective for nose symptoms. In a ﬁ  rst 
placebo-controlled trial on subjects with ragweed-induced 
rhinitis, only patients with a signiﬁ  cant decrease in IgE 
levels, and thus requiring higher doses of omalizumab – up 
to 375 mg every 2 weeks – showed a clinical efﬁ  cacy (Casale 
et al 1997). The same author conducted a dose-response 
study, randomly assigning patients to receive 50, 150, or 
300 mg of omalizumab, or placebo immediately before 
and during the ragweed pollen season; the dose of 300 mg 
was signiﬁ  cantly more effective than placebo in reducing 
symptoms scores and consumption of antihistamines and in 
improving quality of life (Casale et al 2001).
Another controlled trial investigated the effects of omali-
zumab in birch pollen-induced rhinitis, using the dose of 
300 mg at intervals of 4 weeks with IgE levels lower than 150 
IU/mL, and 3 weeks with IgE levels higher than 150 IU/mL 
(Adelroth et al 2000). The results showed a better outcome in 
patients with free IgE levels decreased to less than 25 IU/mL, 
who comprised 70% of those actively treated, and signiﬁ  cant 
differences in favor of omalizumab for eye (but not nose) 
symptoms, use of rescue medication, patient’s evaluation of 
efﬁ  cacy, and quality of life.
Efﬁ  cacy of anti-IgE treatment was also evident from 
studies of perennial allergic rhinitis, which demonstrated 
signiﬁ  cant advantage over placebo for symptom scores, 
use of rescue medication, and quality of life (Chervinsky 
et al 2003). Of particular interest is the SOLAR (Study of 
Omalizumab in comorbid Asthma and Rhinitis) study, a 
randomized controlled trial dealing with 405 patients with 
moderate to severe allergic asthma and concomitant moderate 
to severe allergic rhinitis (Vignola et al 2004). The outcome 
measures were the number of acute asthma exacerbations 
and the score obtained from a combined asthma and rhinitis 
quality of life questionnaire. Signiﬁ  cant differences in favor 
of omalizumab were observed for both parameters (p = 0.02 
for asthma exacerbations, p   0.001 for quality of life), and 
the signiﬁ  cance was found for quality of life with the rhini-
tis questionnaire alone. Rhinitis symptoms were taken into 
account also in the study by Ayres et al; the symptom scores 
present data showing that the addition of omalizumab to the 
standard drug treatment signiﬁ  cantly ameliorated asthma, 
rhinitis, and their combination (Ayres et al 2004).
IgE-mediated skin disorders
Atopic dermatitis is a quite common skin disease in childhood, 
not uncommon also in allergic adults, in which the elevated 
and persistent production of IgE antibodies plays an important 
role (Leung et al 2003). This makes such a disorder a possible Biologics: Targets & Therapy 2008:2(1) 71
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target of anti-IgE treatment, but thus far there are scant data 
on the effects of omalizumab in atopic dermatitis. A ﬁ  rst study 
on 3 adult patients (mean age 39 years) with severe atopic 
dermatitis (AD) treated for 4 months with a dose of 450 mg 
every other week – that is, exceeding the currently maximum 
recommended dose – failed to demonstrate any beneﬁ  t (Kra-
then et al 2006). Positive results were instead observed in 3 
pediatric patients (mean age 11 years) with severe AD who 
had not beneﬁ  ted previously from any treatment but showed 
a clear improvement with anti-IgE (Lane et al 2006), and in 
a series of 7 patients including 2 children and 5 adults (mean 
age 31 years) treated with omalizumab for persistent uncon-
trolled asthma but presenting also AD since early childhood 
(Vigo et al 2006): 2 patients had a severe, 5 a moderate, and 
1 a slight stage of disease. In the two positive studies, doses 
corresponding to recommended, according to individual 
weight and IgE level, were used except for a 13-year-old 
child with a serum IgE level of 6120 IU/mL who was treated 
with a 450 mg dose. The level of total IgE appeared a critical 
factor, considering that the three patients in the unsuccessful 
study had a mean starting level of 17.600 IU/mlL(Krathen 
et al 2006) compared with a mean level of 3600 IU/mL in the 
pediatric study (Lane et al 2006), and of 1060 IU/mL in the 
study on adults and children (Vigo et al 2006).
However, the available data on omalizumab in AD can-
not indicate the optimal level of IgE for predicting a positive 
response to treatment and, as noted by the authors of the 
studies, well-designed controlled trials are needed to explore 
such issue, comparing patients with different IgE levels. 
In any case, levels higher than recommended for asthma 
deserve to be evaluated, considering that the suggested 
limit level of 700 IU/mL when applied to AD is likely to be 
associated with milder stage of disease which, similarly to 
rhinitis, may hardly warrant an expensive biologic therapy 
(Beck et al 2006).
Another possible target could be IgE-mediated urticaria: 
a recent report described a girl with moderate persistent 
asthma and cold-induced urticaria who had complete 
resolution of her urticaria following treatment with anti-IgE 
(Boyce 2006). This led Wanderer to propose in an editorial 
article a reconsideration of the potential pathogenetic role 
of IgE in cold-induced as well as in other forms of urticaria 
(Wanderer 2007).
Adverse reactions to foods
Hypersensitivity to foods affects about 3%–4% of the popula-
tion, with higher prevalence in children (Kanny et al 2001), 
but the major concern is for anaphylaxis, which may cause 
fatal reactions often after inadvertent consumption of the 
culprit food (Bock et al 2001). In US the most frequently 
responsible food is peanut, which is estimated to cause 
50–100 deaths per year. An important randomized controlled 
study was conducted on 84 patients with allergic reactions 
to peanut, randomly assigned to receive anti-IgE in doses of 
150, 300, or 450 mg, respectively, or placebo (Leung et al 
2003). The results showed a signiﬁ  cantly higher effective-
ness with the 450 mg dose, which increased the threshold of 
sensitivity to peanut, assessed by oral challenges, from an 
average of about half a peanut (178 mg) to almost 9 peanuts 
(2805 mg), an amount far higher than most inadvertent 
ingestion. This suggests for anti-IgE treatment the capacity 
to prevent fatal reactions and warrants for further investiga-
tions with other foods involved in anaphylaxis.
Anti-IgE and allergen 
immunotherapy
Allergen immunotherapy is the practice of administering 
allergen extracts to induce a tolerance in allergic subjects and 
is the only treatment able to interfere with the natural history 
of allergic diseases (Bousquet et al 1998). The conventional 
form of immunotherapy is administered subcutaneously, but 
the occurrence of systemic adverse reactions, sometimes 
even life-threatening (Stokes et al 2006), stimulated the 
search for non-injective routes, which eventually led to the 
introduction and validation of sublingual immunotherapy 
(Canonica et al 2003), in terms of clinical efﬁ  cacy and safety 
(Wilson et al 2005). The aims of adding anti-IgE treatment 
to immunotherapy are to (i) prevent or reduce the adverse 
effects of subcutaneous route and (ii) improve the efﬁ  cacy 
of subcutaneous or sublingual route.
Concerning the ﬁ  rst objective, a recent placebo-controlled 
study (Casale et al 2006) demonstrated that pre-treatment 
with omalizumab resulted in a 5-fold decrease of risk of ana-
phylactic reactions in patients with ragweed-induced rhinitis 
undergoing immunotherapy by a rush schedule, which has 
the advantage of reaching quickly the maintenance dose but 
raises the likelihood of adverse reactions. This ability of the 
anti-IgE treatment has interesting possible applications in 
immunotherapy with Hymenoptera venom, which warrants 
rush schedules to achieve rapid protection from stings but 
must face the problem of adverse reactions, particularly wor-
rying when honeybee venom is used (Muller et al 1992).
The study by Casale et al investigated also the efﬁ  cacy 
by an intent-to-treat analysis, and found that the combination 
of omalizumab and immunotherapy signiﬁ  cantly improved 
symptom scores during the ragweed season compared with Biologics: Targets & Therapy 2008:2(1) 72
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immunotherapy alone (Casale et al 2006). This conﬁ  rmed 
the results of two previous studies dealing (Kuehr et al 
2002; Rolinck-Werninghaus et al 2004). In a multi-center 
randomized controlled trial on 221 children and adolescents 
with seasonal rhinitis caused by birch and grass pollen, the 
combination therapy of anti-IgE and immunotherapy – started 
14 weeks before the pollen season – was signiﬁ  cantly more 
effective than immunotherapy alone for both pollens (Kuehr 
et al 2002). It is of particular interest that patients receiving 
combination treatment required almost no additional rhinitis 
medication. By studying children allergic to grass pollen, 
the comparison of subjects treated with a combination of 
omalizumab and immunotherapy with those treated with 
monotherapies by either anti-IgE or grass immunotherapy 
showed a higher efﬁ  cacy of the combined treatment (Rolinck-
Werninghaus 2004). An apparent advantage of adding 
omalizumab to allergen immunotherapy is that anti-IgE 
treatment is not allergen speciﬁ  c and thus is effective also 
on symptoms induced by other allergens in polysensitized 
patients (Hamelman et al 2002).
Concluding remarks
The anti-IgE monoclonal humanized antibody omalizumab 
is a biologic agent which has demonstrated important clini-
cal effects in patients with severe asthma uncontrolled by 
conventional drug treatment, and is currently considered 
a treatment option in international guidelines on asthma 
therapy. Its ability to reduce circulating IgE antibodies and 
consequently the IgE-mediated manifestation makes possible 
its use in a number of clinical conditions, with a particular 
advantage for hypersensitivity reactions with a favorable 
cost-beneﬁ  t ratio.
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